Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

Rhea-AI Summary

Tempest Therapeutics, a clinical-stage oncology company, announced participation in the Emerging Technologies for IO Targeting and Discovery Summit on October 13-14, 2022. Dara Burdette, Ph.D., will chair a session on 'New Approaches to Solid Tumor Targeting' and present on the TREX1 pipeline asset. Additionally, Nicholas DeVito, M.D., will share preclinical data on TPST-1495, a dual inhibitor targeting EP2 and EP4 receptors. Both presentations aim to enhance understanding of tumor-targeted therapies and immune response.

• Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” Session
  
• Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company’s TREX1 pipeline asset and will serve as chairperson for the “New Approaches to Solid Tumor Targeting” session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA.

TREX1 Presentation

Dr. Burdette’s presentation will describe the company’s approach to identify and characterize novel small molecule inhibitors of the 3’-5’ DNA repair exonuclease, TREX1. TREX1 inhibits cGAS/STING signaling and is induced in tumor cells due to genetic instability or therapeutic intervention. Tempest’s program aims to generate an anti-tumor response through selectively activating the STING pathway in advanced metastatic cancers with orally available small molecule inhibitors of TREX1.

Presentation details:

Title:	Small Molecules Targeting the 3’-5’ DNA Repair Exonuclease TREX1 Selectively Activate the STING Pathway and Induce Tumor-Specific Immunity
Date:	Thursday, October 13, 2022
Time:	2:40 p.m. EDT

TPST-1495 Presentation

In addition, Nicholas DeVito, M.D., a medical oncologist and medical instructor in the laboratory of Dr. Brent Hanks, M.D., Ph.D. at Duke University School of Medicine, will be giving a presentation describing pre-clinical results with TPST-1495, Tempest’s clinical-stage dual inhibitor of the EP2 and EP4 prostaglandin E2 receptors, in mice bearing tumors with designated gene expression profiles.

Presentation details:

Title:	Understanding Tumor-Mediated Immune Evasion to Develop Biomarkers toward Rational Therapeutic Combinations
Date:	Wednesday, October 12, 2022
Time:	8:40 a.m. EDT

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

---

¹ If approved by the FDA

FAQ

What is the focus of Tempest Therapeutics' presentation at the Emerging Technologies for IO Targeting Summit?

Tempest Therapeutics will focus on their TREX1 pipeline asset and chair the session on 'New Approaches to Solid Tumor Targeting'.

Who will present the preclinical data on TPST-1495?

Nicholas DeVito, M.D., will present preclinical data on TPST-1495 at the summit.

When is Tempest Therapeutics presenting their TREX1 research?

The presentation on TREX1 will take place on October 13, 2022, at 2:40 p.m. EDT.

What is TPST-1495 in relation to tumor treatment?

TPST-1495 is a clinical-stage dual inhibitor targeting EP2 and EP4 prostaglandin E2 receptors, aimed at enhancing immune response against tumors.

What is the objective of the research on TREX1?

The research aims to develop small molecule inhibitors that activate the STING pathway to induce anti-tumor responses in advanced metastatic cancers.